View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 16, 2022

Genprex to progress Phase I/II trial of non-small cell lung cancer therapy

Progression-free survival is the primary endpoint of the Phase II portion of the trial.

Genprex has received approval from the Safety Review Committee (SRC) to advance the Phase I/II Acclaim-1 clinical trial of Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), plus AstraZeneca’s Tagrisso (osimertinib), for treating late-stage, non-small cell lung cancer (NSCLC).

The approval comes after SRC reviewed the first cohort of subjects in the Phase I segment of the trial and recommended increasing the dose in the second cohort of the Phase I trial.

The open-label, multicentre trial is analysing Reqorsa plus Tagrisso in late-stage NSCLC patients with activating epidermal growth factor receptor (EGFR) mutations, whose disease has progressed following Tagrisso treatment. 

It has up to three sequential dose escalation cohorts, in which patients will be given intravenous (IV) Reqorsa on day one, along with an 80mg osimertinib oral tablet daily during the 21-day treatment cycles until disease progression is stopped or unacceptable toxicity is reached. 

The Phase I dose escalation trial is anticipated to enrol up to 18 subjects to detect the maximum tolerated dose of the combination therapy. 

The Phase II segment is planned to have nearly 74 subjects who will be randomised in a 1:1 ratio to receive either Reqorsa and Tagrisso combination treatment or Tagrisso as a single agent. 

Progression-free survival, defined as the time from randomisation to progression or morality, is the primary endpoint of this portion.

Genprex plans to conduct an interim assessment on reporting 25 events. 

A lead drug candidate of the company, Reqorsa is a pan-kinase inhibitor. It consists of a tumour suppressor gene, TUSC2 gene, as the active ingredient. 

Genprex chief medical officer Mark Berger said: “The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports Reqorsa’s safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most. 

“Enrollment in Acclaim-1 remains on track to complete the Phase 1 portion of the study by year end.” 

In March this year, the company dosed the first subject in Phase I/II trial of Reqorsa plus Tagrisso for late-stage NSCLC.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena